Clinical trial NCT03389997: Assessement of Viral Shedding Duration After a Respiratory Tract Infection in Oncology and Hematology Patients
Official title: Assessement of Viral Shedding Duration After a Respiratory Tract Infection in Oncology and Hematology Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Respiratory Tract Viral Infection
Keywords: respiratory tract infections
virus shedding
cancer
Immunocompromised Host
Lead sponsor: Poitiers University Hospital
Sponsor class: OTHER
First posted: 2018-01-04
Enrollment: 44
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Iterative nasal swabs will be performed to screen for virus shedding
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to assess the duration of the viral shedding in hematology and oncology patients after a respiratory tract viral infection. This duration has not been much studied in that population whereas it is probably longer than that in immunocompetent patients. Thereby it may be a source of transmission amongst these immunocompromised patients.

Detailed description: The development of multiplex polymerase chain reaction (PCR) tests has greatly improved the diagnosis of respiratory tract viral infections by increasing its sensitivity and the diversity of viral species detected. However, there are few data concerning respiratory tract viral infections amongst hematology and oncology patients. Especially, the duration of viral shedding following an infection has not been much studied whereas it is a source of inter-individual transmission between immunocompromised patients who are more likely to develop severe disease.

Studies conducted so far concerned mainly hematology patients. They have shown that viral carriage could last up to one month and a half in some patients with hematological malignancy.

The aim of this study is to determine the duration of the viral shedding in patients from hematology and oncology units after a respiratory tract viral infection for the ten main viruses involved in order to better manage these infections and to better prevent their transmission.

Eligibility criteria: Inclusion Criteria:

* Patient with solid organ cancer or haematological malignancy with or without chemotherapy
* Having symptoms of upper and/or lower respiratory tract infection
* Virus detected by PCR in nasal sample
* Signature of consent

Exclusion Criteria:

* Hematological stem cell and solid organ recipients
* No health insurance
* protected people

Primary outcomes:
measure: Nasal carriage of virus after a viral respiratory tract infection
timeFrame: Up to 1 year
Secondary outcomes:
measure: Prevalence of upper and lower respiratory tract infections
timeFrame: 2 years
measure: Prevalence of viral coinfections
timeFrame: 2 years
measure: Prevalence of bacterial coinfections
timeFrame: 2 years
measure: transmission of respiratory tract viral infections by relatives
timeFrame: 2 years
measure: respiratory complications due to respiratory tract viral infections
timeFrame: 2 years
measure: extra-pulmonary symptoms due to respiratory tract viral infections
timeFrame: 2 years
measure: effect of influenza vaccine on viral shedding
timeFrame: 2 years
measure: risk factors to do severe form of respiratory tract infection
timeFrame: 2 years
measure: nosocomial transmission of respiratory tract viral infection
timeFrame: 2 years
measure: delay of chemotherapy due to respiratory infection
timeFrame: 2 years
measure: survival after a respiratory tract viral infection
timeFrame: 30 days
measure: TTV viral load as a marker of immunodepression in oncology and hematology patients
timeFrame: 2 years
measure: Correlation between TTV viral load and duration of viral shedding and severity of respiratory tract infection
timeFrame: 2 years
Other outcomes:
Locations:
city: Poitiers
country: France
facility: University Hospital of Poitiers
Study officials:
affiliation: CHU of POITIERS
name: France CAZENAVE-ROBLOT, MD,PhD
role: PRINCIPAL_INVESTIGATOR
References: